Identification | Back Directory | [Name]
PNU 100480 | [CAS]
168828-58-8 | [Synonyms]
CS-2604 U-100480 Sutezolid PNU 100480 PF-02341272 Sutezolid (PNU-100480) Sutezolid >=98% (HPLC) PNU-100480; U-100480; PF-02341272 Sutezolid (PNU-100480, PF-02341272) PNU 100480 - PF 02341272 | U 100480 | Sutezolid (S)-N-((3-(3-fluoro-4-thiomorpholinophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide (S)-N-[[3-[3-Fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide Acetamide, N-[[(5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (S)-N-((3-(3-fluoro-4-thiomorpholinophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide(WXC06631) | [Molecular Formula]
C16H20FN3O3S | [MDL Number]
MFCD00937821 | [MOL File]
168828-58-8.mol | [Molecular Weight]
353.41 |
Chemical Properties | Back Directory | [Melting point ]
186-187°C | [Boiling point ]
609.0±55.0 °C(Predicted) | [density ]
1.321±0.06 g/cm3(Predicted) | [storage temp. ]
room temp | [solubility ]
DMSO: soluble20mg/mL, clear | [form ]
powder | [pka]
15.53±0.46(Predicted) | [color ]
white to beige | [optical activity]
[α]/D -8 to -12°, c = 1 in chloroform-d |
Hazard Information | Back Directory | [Description]
PNU 100480 is an oxazolidinone antibiotic that is active against multidrug resistant tuberculosis. It inhibits the growth of M. tuberculosis replicating and nonreplicating strains (MIC = ~400 ng/ml for both) and of clinical isolates that are susceptible or resistant to a combination of isoniazid , rifampin (rifampicin; ), ethambutol , and streptomycin (; MICs = ≤0.0625-0.5 mg/L). It also inhibits the growth of P. insidiosum and P. aphanidermatum clinical isolates (MICs = 4-64 μg/ml). PNU 100480 (100 mg/kg per day) decreases the number of colony forming units (CFU) in the lung in a mouse model of systemic nonreplicating M. tuberculosis infection. | [Uses]
Sutezolid is an oxazolidinone antibacterial agent analog. Sutezolid is a promising antimycobacterial agent (tuberculostatic). | [Biochem/physiol Actions]
Sutezolid (PNU 100480) is an oxazolidinone antimicrobial. Sutezolid inhibits protein synthesis by inhibiting bacterial mRNA translation. Sutezolid is being investigated for the treatment of multiple drug–resistant and extensively drug-resistant tuberculosis. The compound is a less toxic and more potent derivative of linezolid. | [storage]
Store at -20°C |
|
Company Name: |
Sigma-Aldrich
|
Tel: |
021-61415566 800-8193336 |
Website: |
https://www.sigmaaldrich.cn |
|